

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Jul 2026

Evaluation of curcumin effect on preventing heart failure after myocardial infarction

Protocol summary

Study aim

Determination the efficacy of curcumin in preventing heart failure after acute myocardial infarction

Design

This is a double blind prospective placebo controlled clinical trial study which can performed in Quam hospital, Mashhad.

Settings and conduct

double blind prospective placebo controlled clinical trial study

Participants/Inclusion and exclusion criteria

patients between 18 and 80 years with STEMI who underwent successful revascularisation on culprit vessel will be included. Patients with previous MI which was lead to ejection fraction less than 50%, malignant ventricular arrhythmia, congenital heart disease, cardiogenic shock, history of suspicious or documented heart failure or decrease in left ventricular ejection fraction, patients candidate for CABG or history of previous CABG, patients with GFR less than 30, patients with autoimmune or connective tissue disorders, subjects with cancer, pregnant or breastfeeding women, psychological patients and persons who can not complete 2-month clinical followup during study, will be excluded.

Intervention groups

Group receiving curcumin and Group receiving placebo

Main outcome variables

Left ventricular ejection fraction

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20130829014521N19**

Registration date: **2022-02-19, 1400/11/30**

Registration timing: **registered_while_recruiting**

Last update: **2022-02-19, 1400/11/30**

Update count: **0**

Registration date

2022-02-19, 1400/11/30

Registrant information

Name

Amirhossein Sahebkar

Name of organization / entity

Mashhad University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 51 1882 9260

Email address

sahebkar@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-07-23, 1400/05/01

Expected recruitment end date

2022-12-22, 1401/10/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of curcumin effect on preventing heart failure after myocardial infarction

Public title

Effect of curcumin on preventing heart failure

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria:

ST elevation myocardial infarction Successful treatment with percutaneous coronary intervention (PCI) on related vessel to infarct

Exclusion criteria:

Previous myocardial infarction lead to ejection fraction less than 50% malignant arrhythmia congenital heart disease cardiogenic shock history of suspicious or documented heart failure or decrease in left ventricular ejection fraction patients candidate for coronary artery bypass graft (CABG) or previous CABG patients with glomerular filtration rate lesser than 30 patients with history of autoimmune or connective tissue disorders patients with cancer pregnant or breastfeeding women patients with previous documented psychological disorders patients who can not complete their 2-month clinical followups during study

Age

From **18 years** old to **80 years** old

Gender

Both

Phase

0

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

Patients will be allocated to 500mg capsule of curcumin (500mg daily) or placebo capsule, by block randomization with block size of 2. In each block, patients of each group will be exist. The order of blocks will be determined randomly in 500mg capsule of curcumin (500mg daily) and placebo capsule groups and subjects will allocated sequentially with order of admitting. Random allocation rule method was used for determination of sequences. Using non-transparent envelopes sealed with random sequences (Sequentially numbered, sealed, opaque envelopes). They are placed in order. In order to maintain the random sequence, numbering is done on the outer surface of the envelopes in the same way. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants in the study, one of the envelopes of the letter will be opened in order and the assigned group of the participant will be revealed.

Blinding (investigator's opinion)

Double blinded

Blinding description

Blinding will be done by complete matching of placebo and drugs by color, size, shape and smell. Patients receive drugs (intervention or placebo groups) in closed pockets which are coded and patients are not aware of their contents. Coding will be done by one of the colleagues of the study and evaluator nurse will be blind for type of drugs.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethical Committee of Mashhad University of Medical Sciences

Street address

Qoreshi

City

Mashhad

Province

Razavi Khorasan

Postal code

9138813944

Approval date

2019-04-17, 1398/01/28

Ethics committee reference number

IR.MUMS.MEDICAL.REC.1398.003

Health conditions studied

1

Description of health condition studied

ST elevation myocardial infarction

ICD-10 code

BA41.0

ICD-10 code description

BA41

Primary outcomes

1

Description

Left ventricular ejection fraction

Timepoint

baseline and 60 days later

Method of measurement

By echocardiography

Secondary outcomes

1

Description

Major adverse cardiovascular events

Timepoint

during hospitalization and 60 days after starting study

Method of measurement

documents and reports of cardiac death, recurrent MI, culprit vessels revascularisation, cardiogenic shock, severe heart failure, major arrhythmia

Intervention groups**1****Description**

Intervention group: curcumin capsule 500 mg

Category

Treatment - Drugs

2**Description**

Control group: placebo capsule 500mg

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Ghaem Hospital

Full name of responsible person

SARA KHAKI

Street address

Ahmadabad

City

Mashhad

Province

Razavi Khorasan

Postal code

9919991766

Phone

+98 935 457 4977

Email

KHAKIS991@mums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Majid Ghayour-Mobarhan

Street address

Qoresh

City

Mashhad

Province

Razavi Khorasan

Postal code

9138813944

Phone

+98 51 3841 1538

Email

vcresraech@mums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Amirhossein Sahebkar

Position

Associated professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Azadi Square

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948954

Phone

+98 51 3180 1100

Email

sahebkar@mums.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Ramin Khameneh

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Cardiology

Street address

Ghaem hospital, Mashhad city, IRan

City

Mashhad

Province

Razavi Khorasan

Postal code

9177899191

Phone

+98 51 1800 2288

Email

khamenehR@mums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Amirhossein Sahebkar

Position

Associated professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

School of Medicine, Vakilabad blvd.

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948954

Phone

+98 51 1882 9260

Fax

+98 51 1882 3251

Email

sahebkar@mums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable

Title and more details about the data/document

After finishing the study, results will be published as article.

When the data will become available and for how long

unlimited

To whom data/document is available

Researchers, Physicians, Pharmacists

Under which criteria data/document could be used

for research purposes

From where data/document is obtainable

request to corresponding author

What processes are involved for a request to access data/document

Sending request to corresponding author and explain the cause of request. If it was confirmed, it will be sent.

Comments